Glucose-lowering therapies and treatments six months before or after coronary angiography were classified into the following dispended groups of medication during this time period and based on registered ATC codes in the Prescribed Drug Register (SGLT2i: ATC code A10BK, GLP-1 RA: ATC code A10BJ...
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016;... E Holly,Gurgle...
Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA.aSGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2,3,4,5,7,11,13], either in a population with T2D and established C...
The evidence for cardiovascular benefit of SGLT2i and GLP1RA has rightfully prompted the diabetes and cardiovascular communities to incorporate these new classes of agents into clinical management guidance. Biguanides Metformin has remained first-line treatment for T2DM due to its efficacy, safety, ...
Of those who discontinued medication, 60.7% of GLP-1RA versus 56.0% of SGLT2i prior users were willing to reinitiate treatment. Conclusions: Patients with T1DM report initiating adjuvant treatment with GLP-1RA and/or SGLT2i to improve glycemic control and lose weigh...
(DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Whereas a variety of conventional antidiabetic drugs have been shown to retard the progression of nephropathy through glycemic control [1], there are a limited number of ...
The likelihood of in-hospital mortality was similar among patients on neither medication compared to patients on both (χ2= 0.06,p= 0.802), GLP-1RA monotherapy (χ2= 0.61,p= 0.435), and SGLT2i monotherapy (χ2= 0.002,p= 0.968). The odds of all-cause readmission within 30 days was ...
The DURATION-8 study evaluated the use of SGLT2 inhibition (dapagliflozin) and GLP-1-RA (once-weekly exenatide), which reduced HbA1c <0.4%, but found an additive BP reduction (4.2 mm Hg). An additive effect on weight loss was also observed in AWARD-10, which studied the GLP-1-RA ...
Since then, there has been widespread debate about the potential risks of using this class of medication, including with regard to theinvestigational and as-yet off-label usein patients with type 1 diabetes. It appears that the majority of DKA cases occur in people who are insulin deficient, ...
doi:10.1161/CIRCULATIONAHA.116.024764 PubMedGoogle ScholarCrossref Association of Race and Ethnicity With Prescription of SGLT2i and GLP-1 RA Among Patients With Type 2 Diabetes JAMA Original Investigation September 6, 2022 This cross-sectional analysis of data from the US Veterans Health ...